儿童癌症长期生存者的化疗诱导周围神经病:临床、神经生理、功能与患者报告结局
这项横断面观察研究连续纳入121例儿童癌症生存者,中位16岁、治疗结束后中位8.5年评估化疗诱导周围神经病,53.0%接受神经毒性化疗者存在临床周围神经病,与感觉轴索性神经病、功能缺陷及患者报告结局下降相关,顺铂较长春碱类更常出现长期神经毒性。
要点
- 儿童癌症生存者中,接受神经毒性化疗者53.0%存在临床周围神经病。
- 周围神经病与下肢为主的感觉轴索性神经病、手灵活度、远端感觉和平衡缺陷相关。
- 周围神经病评分与患者报告的总体生活质量和躯体功能下降相关。
核心结论
- 儿童癌症生存者中归因于周围神经病的临床异常常见且长期持续,同时伴有患者报告结局的缺陷。
- 筛查长期神经病时应考虑神经毒性药物类型和有针对性的临床神经评估。
- 进一步开发周围神经病特异性的儿科评估工具有助于神经保护和康复策略的研究。
研究设计与样本
- 横断面观察研究,2015年4月至2016年12月从单一三级医院癌症生存门诊连续招募17岁前因颅外恶性肿瘤接受化疗的癌症生存者,并与健康年龄匹配对照比较;研究者对化疗类型设盲。
- 169例符合纳入标准,其中48例(28.4%)无法联系或拒绝参与,最终纳入121例儿童癌症生存者。
主要发现
- 121例中65例(53.7%)为男性,神经毒性评估的中位(范围)年龄为16(7-47)岁,治疗完成后中位(范围)8.5(1.5-29)年。
- 接受神经毒性化疗的100例中53例(53.0%)存在符合周围神经病的临床异常,平均Total Neuropathy Score增加2.1(95%CI 1.4-2.9;P < .001)。
- 临床异常与下肢为主的感觉轴索性神经病相关,平均波幅降低5.8 μV(95%CI 2.8-8.8;P < .001)。
- 功能缺陷见于手灵活度、远端感觉和平衡。
- 患者报告结局显示总体生活质量和躯体功能下降,且与Total Neuropathy Score相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In light of the excellent long-term survival of childhood cancer patients, it is imperative to screen for factors affecting health, function, and quality of life in long-term survivors. OBJECTIVE: To comprehensively assess chemotherapy-induced peripheral neuropathy in childhood cancer survivors to define disease burden and functional effect and to inform screening recommendations. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional observational study, cancer survivors who were treated with chemotherapy for extracranial malignancy before age 17 years were recruited consecutively between April 2015 and December 2016 from a single tertiary hospital-based comprehensive cancer survivorship clinic and compared with healthy age-matched controls. Investigators were blinded to the type of chemotherapy. A total of 169 patients met inclusion criteria, of whom 48 (28.4%) were unable to be contacted or declined participation. EXPOSURES: Chemotherapy agents known to be toxic to peripheral nerves. MAIN OUTCOMES AND MEASURES: The clinical peripheral neurological assessment using the Total Neuropathy Score was compared between recipients of different neurotoxic chemotherapy agents and control participants and was correlated with neurophysiological, functional, and patient-reported outcome measures. RESULTS: Of the 121 childhood cancer survivors included in this study, 65 (53.7%) were male, and the cohort underwent neurotoxicity assessments at a median (range) age of 16 (7-47) years, a median (range) 8.5 (1.5-29) years after treatment completion. Vinca alkaloids and platinum compounds were the main neurotoxic agents. Clinical abnormalities consistent with peripheral neuropathy were common, seen in 53 of 100 participants (53.0%) treated with neurotoxic chemotherapy (mean Total Neuropathy Score increase, 2.1; 95% CI, 1.4-2.9; P < .001), and were associated with lower limb predominant sensory axonal neuropathy (mean amplitude reduction, 5.8 μV; 95% CI, 2.8-8.8; P < .001). Functional deficits were seen in manual dexterity, distal sensation, and balance. Patient-reported outcomes demonstrating reduction in global quality of life and physical functioning were associated with the Total Neuropathy Score. Cisplatin produced long-term neurotoxicity more frequently than vinca alkaloids. CONCLUSIONS AND RELEVANCE: Clinical abnormalities attributable to peripheral neuropathy were common in childhood cancer survivors and persisted long term, with concurrent deficits in patient-reported outcomes. Both the type of neurotoxic agent and a targeted clinical neurological assessment are important considerations when screening survivors for long-term neuropathy. Further development of peripheral neuropathy-specific pediatric assessment tools will aid research into neuroprotective and rehabilitative strategies.
引用
- Kandula T, Farrar MA, Cohn RJ, et al. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes. JAMA Neurol. 2018. PMID: 29799906. doi:10.1001/jamaneurol.2018.0963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。